Skip to main content
MEDS
NASDAQ Life Sciences

Q3 Revenue Jumps 50% Sequentially as DataMEDS Swings to $10.5M Operating Profit

Tom Rudovsky · Reported by ACCESS Newswire
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.88
Mkt Cap
$3.951M
52W Low
$0.82
52W High
$35.5
52W Position info
7.3% above low
Off High info
98% below high
Rel. Volume
Market data snapshot near publication time

MEDS is trading near its 52-week low of $0.82 (7.3% above the low).

Summary

DataMEDS reported Q3 2026 revenue up 50% sequentially, driven by its Corexa Pharmacy unit, and swung to a $10.535 million net operating profit from a $34.318 million operating loss a year earlier. Net profit per share was $2.72 on 3.961 million weighted average shares. The profit is largely accounting-driven: the company credits extinguishment of debt and litigation liabilities tied to prior management plus lower management compensation and G&A, not just operating gains. That matters because the last 10-Q (August 17) showed a $26.1M loss, going concern doubt and a Nasdaq equity deficiency — this release says full Nasdaq compliance, including the net equity requirement, was regained October 19. Management also flagged new revenue channels: a non-binding MOU with a Florida HMO covering 25,000+ members (definitive agreements expected in Q4 2026), a November launch of compounded peptides, the REBOOT GLP-1 license, and the Helomics diagnostics lab acquired in September. Watch whether the HMO MOU converts to a definitive agreement in Q4 and whether the profit repeats once one-time debt extinguishment gains drop out.

At the time of this announcement, MEDS was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.82 to $35.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.


Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $0.700 info
Change: -$0.0499 (-7%) info
Market Cap: $3.342M info
MEDS
Nov 10, 2026, 4:30 PM EST
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $0.9215
Real-time Price: $0.700 info
Change: -$0.2215 (-24%) info
Market Cap: $3.342M info
MEDS
Nov 05, 2026, 6:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.51
Real-time Price: $0.700 info
Change: -$0.810 (-54%) info
Market Cap: $3.342M info
MEDS
Nov 03, 2026, 6:18 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $1.70
Real-time Price: $0.700 info
Change: -$1.00 (-59%) info
Market Cap: $3.342M info
MEDS
Oct 26, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.14
Real-time Price: $0.700 info
Change: -$1.44 (-67%) info
Market Cap: $3.342M info